<DOC>
	<DOC>NCT00685113</DOC>
	<brief_summary>This is a multicenter study to evaluate the efficacy and safety of 2 different doses of DR-3001. For eligible subjects the duration of the study will be approximately 20 weeks; this will consist of a 4-week screening period, a 12-week treatment period and a 4-week follow-up period. Subjects will have physical and laboratory exams, including blood draws at each scheduled visit. Subjects will be required to insert a vaginal ring (replacing it every 4 weeks) and to keep a daily record of their toilet voids (including time,type and volume) for 3 days at several specified time points.</brief_summary>
	<brief_title>A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<criteria>Women 18 years of age or older, ambulatory, with a history and presentation consistent with urge incontinence â‰¥ 6 months Able to distinguish between stress and urge incontinence During the Screening Period able to demonstrate the presence of overactive bladder with urge incontinence based on diary entries Others as dictated by FDAapproved protocol Stress incontinence, continuous incontinence or overflow urinary incontinence Chronic illness, neurological dysfunction or injury that could cause incontinence Pregnant, breastfeeding, or gave birth in the last 6 months Others as dictated by FDAapproved protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>